Intel shares closed at $104.70 on October 9, down 2.22%, as investors continued to question how much value Intel would capture from Elon Musk’s Terafab project. CEO Lip-Bu Tan said Intel would remain involved, but that confirmed participation—not the size, economics or certainty of any business.
2
3
The evidence provided here confirms the October 9 closing price and documents the Terafab uncertainty. It does not independently verify the claimed five-session loss or trading-volume comparison, so those figures should not be treated as an explanation for the decline.
Why continued involvement did not settle the issue
Intel had been Terafab’s first publicly named foundry partner, and reporting identified its next-generation 14A process as the only manufacturing process named for the project at the time.
4
23
25 That made Elon Musk’s confirmation of early discussions with Taiwan Semiconductor Manufacturing Co. (TSMC) consequential: investors had to consider whether Intel’s role might change even if the partnership continued. The discussions were described as preliminary, with no agreement reported.
5
23
Tan’s October 7 comments reaffirmed that Intel would keep working with Terafab. He made them ahead of an event marking Intel’s 50th year of operations in Japan.
3
5 But the statement did not quantify Intel’s work or establish what revenue, if any, the project would generate. Reporting after the comments continued to identify uncertainty over Intel’s specific role as a concern for investors.
1
2
TSMC talks are not the same as a takeover
Musk said his companies would build and operate Terafab themselves, while TSMC might sublease part of the facility. That account weighs against interpreting the talks as a confirmed TSMC takeover, but it does not resolve whether TSMC could take on some other role or how responsibilities would be divided.
6
7
The distinctions matter for Intel. A project can keep a company involved without making it the main manufacturer or guaranteeing a particular volume of work. The reporting available here does not establish Intel’s exact responsibilities or whether Terafab will place manufacturing orders with Intel Foundry.
1
21
What Intel could earn—and what remains unknown
The commercial terms are the central gap. The available reporting does not specify Intel’s investment, contractual duties, licensing fees, purchase guarantees or the timing of any revenue.
1
21
Depending on the eventual arrangement, Intel’s contribution could potentially include technology access or licensing, engineering support, manufacturing, or other services. Those are possible business models, not confirmed contract terms. The current evidence does not show which, if any, would apply—or whether Intel would earn revenue by manufacturing wafers in its own fabs.
That uncertainty helps explain why a high-profile project association may not, by itself, answer investors’ questions about Intel Foundry’s business prospects. Participation is not a disclosed order, and a named process is not evidence of a specific financial return.
What to watch in Intel’s next results
Intel’s third-quarter report, scheduled for October 29, is a near-term opportunity to assess operating performance, with gross margin identified as a key investor focus.
9 In its second-quarter results, Intel reported about $16.1 billion in revenue, up 25% year over year, according to the supplied reporting.
49 The company’s published third-quarter guidance was revenue of $15.8 billion to $16.8 billion and non-GAAP earnings per share of $0.38; it also guided to a 42% non-GAAP gross margin.
48
Those figures provide a company-wide earnings benchmark, not a Terafab revenue forecast. Investors still need clearer evidence of the project’s terms and Intel’s role to judge whether it can contribute meaningfully to the foundry business.
MarketBeat reported an average “Hold” rating and a $109.06 consensus price target in its October 9 coverage. That target is an analyst estimate, not a guarantee of future performance.
9
For now, the best-supported explanation for the October 9 decline is that Intel’s continued involvement did not remove uncertainty about the value of its Terafab role. The next meaningful evidence will be concrete commercial details—and, separately, whether Intel’s results show progress against its financial guidance.